Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.

依托泊苷或者烷化剂的治疗应该每年血细计数，监测骨髓发育不良或继发性白血病的发生迹象。